[October 30, 2014]

EBS Technologies Opens Its Second Clinic, Reports Continuing Efficacy Using Noninvasive Electrical Brain Stimulation System Designed to Expand Visual Field of Patients with Impaired Vision

EBS Technologies ("EBS") announced today that it has opened a second clinic in Germany to treat patients who have impaired vision using its patented noninvasive electrical brain stimulation system- NEXT WAVE (News - Alert)™-to expand the patients' visual field.

A clinical study ("Brain functional connectivity network breakdown and restoration in blindness") published recently in the journal Neurology® validated non-invasive brain stimulation for restoring partial vision to an impaired eye. The Company's NEXT WAVE™ system is a non-invasive brain stimulation device that is designed to expand the visual field of patients with impaired vision caused by glaucoma or stroke or other neurological diseases. NEXT WAVE™ is approved for sale in Europe.

CLICK HERE FOR NEXT WAVE® ANIMATION (ENGLISH)

CLICK HERE FOR NEXT WAVE™ ANIMATION (GERMAN)

"The results we are seeing in the two clinics offering NEXT WAVE therapy validate that repetitive transorbital alternating current stimulation (rtACS), otherwise known as electrical brain stimulation, can absolutely reactivate residual capabilities of brain function," said Anton Federov, MD, Neurologist, co-author of the study published in Neurology and co-founder of EBS Technologies. "We are very pleased to see the significant improvement our patients are manifesting as a result of the rtACS-based NEXT WAVE therapy, and the plan now is to make NEXT WAVE therapy available at neuroophthalmologic and neurorehabilitation clinics throughout Europe."

"There is a dramatic unmet clinical need for treating vision impairment caused by a variety of ophthalmological and neurological disorders. In fact, three out of five persons disabled from impaired vision as a result of optic nerve neuropathy, for example, or brain injury or stroke, are potentially treatable with our NEXT WAVE™ therapy, which is why we are getting enquiries from patients throughout Europeand as well as the United States and Asia," added Ulf Pommerening, CEO of EBS Technologies.

In June 2013, EBS announced the results of a multi-center, 82-patient clinical trial of its NEXT WAVE™ brain stimulation device. About one-half of the clinical trial patients were given a 40-minute treatment protocol for 10 consecutive days with the NEXT WAVE™ device. With an average increase of 24 percent of the total visual field, NEXT WAVE™-treated patients showed significantly better improvements of their total visual field compared with patients in the control group who did not receive NEXT WAVE™ stimulation. All patients had vision impairment lasting at least six months prior to the clinical trial and had exhausted all standard therapeutic options to improve their vision.

About NEXT WAVE™
The NEXT WAVE™ technology enables a unique and patient-centric revitalization of selective communication paths between neurological cells, which may have been impaired due to brain injury caused by e.g. trauma, degeneration, tumor resection, glaucoma or stroke. The non-invasive therapy utilizing the patented NEXT WAVE™ technology is clinically validated to restore vision impairment by 20 to 30 percent after optical pathologies. Contact EBS Technologies for further information: [email protected], +49 (0) 3302 202 2700

NOTE: NEXT WAVE™ is approved for sale in Europe; it is not approved for sale or investigational use in the U.S.

[ Back To TMCnet.com's Homepage ]